inthetrenches, thanks for that. I do know one thing about micro-cap biotech companies in clinical-stage trials: the CEOs always hedge. Why? Simple: money. Seen it time and time again, and retail gets worked up over nothing. I mean, just take AD trials. I bet if you go back over the 99.6% of trials that have failed, 99.6% of the CEOS were confident that they would succeed. Furthermore, if you take the message boards of the 99.6%, 100% of the posters were optimistic--and pessimistic on every other stock that wasn't their own. Yah, I'm cynical, for good reason.
I am long; likewise with AVXL. In fact, I added a bit this morning. I am looking forward to the venue where Ph2b data will be presented.
Market Data 
Markets 
AI
